Senior Scientific Investigator, Chemometrician at GlaxoSmithKline
"Although I know John for just about a year and worked with him only remotely and occasionally during an eight-month time period, but I feel very privileged to know him both personally and professionally and learn his absorption rate analysis method. John has a unique skill in analyzing and interpreting pharmacokinetic data and other relevant data. His skill was based on many years' experience and accumulation of knowledge in biopharmaceutics, pharmacology, chemistry, modeling, etc.. John can identify problematic development approaches by analyzing very limited data and help project teams save months or even years of development and clinical trial time. What is more valuable for John's analysis is that he can extract insightful information from data that can be considered irrelevant or useless."
Research Scientist at GlaxoSmithKline
"John's insight into the complex relationships among physiology, drug delivery and resulting pharmacokinetics has been an invaluable asset to our team. His proficiency at delving deeply into complex data sets often leads to the discovery of critical details and explanations that would otherwise have been missed. The benefits of John's involvement include cost and time savings, optimization of preclinical and clinical study designs, and the ability to apply key learnings to a wide range of products. I highly recommend his expertise as a valuable asset to any project dependent on in vivo data interpretation."
Expert Clinical Pharmacologist, Shire Pharmaceuticals
"I have worked with John on several antiviral projects over the years and most recently on one of the key assets at GSK. He utilized a IVIVC analysis to elucidate the absorption sites of the drug which in turn helped to formulate the dosing instruction for a subgroup of HIV patients who are in need of this drug but can only take the drug on feeding tubes. This not only saved money for the company (by eliminating the need to run a clinical study), but most importantly helped meet patients' need. His in-dept knowledge in biopharmaceutical sciences, extensive experience on formulation development on numerous GSK compounds, and strong quantitative skills make him the go-to person (for me and many others) on issues related to drug absorption and formulation development."
R&D Senior Director at GlaxoSmithKline
"John utilised his expertise in pharmacokinetic modeling to refine our understanding of the exposure of metformin, an 'old-fashioned' drug, but one with huge medical importance and fascinating gastrointestinal pharmacology."
Director at GSK
"John contributed significantly to the understanding to a drug development issue we had with drug absorption. His knowledge about biopharmaceutics and its effect on drug absorption was key to solving our problem. Additionally, he has excellent skills at modeling and simulation of drug absorption situations. Highly recommend him if you need this type of expertise."
Director at Parexel in Quantitative Clinical Development
"John is an expert in the biopharmaceutical research. He has very strong understanding on the pharmaceutical product development as well as pharmacokinetics and hands-on experience with WinNonlin, IVIVC, deconvolution and more. I have worked with John several times on challenging projects which has some hard-to-interpret PK results due to food or drug-drug interactions, and John was able to investigate and provided biopharmaceutical rationale on such PK behaviors. John's expertise helped me and/or the project team to have better understanding on human PK. For example, when we did a 7-drug cocktail drug interaction study and found some unexpected results, John investigated the unexpected drug interactions using his expertise for the team. He was successful in identifying the physiological changes that contributed to the unexpected drug interactions. His conclusions were communicated to and accepted by the medical staff and clinical researchers at both the clinical sites as well as the project team. I strongly recommend John for his expertise in biopharmaceutical research."
Manager at GlaxoSmithKline
"I have worked with John Roush over the last 8 years on a range of pharmaceutical development projects. John is an independent professional with many years experience of biopharmaceutics and formulation development. I value the insight John has given me on development projects. In particular I have found his reviews of the individual plasma concentration vs. time profiles of preclinical and clinical studies useful in understanding the cause of poor and/or variable exposure. This work has been used to drive the decision on project progression based on if the cause poor and/or variable exposure is the API or the formulation. Identifying which projects that have issues due to properties of the API which cannot be addressed with formulation is key to saving time and/or money on projects that will never make it to market."
Manager at GlaxoSmithKline R&D
"I have worked with John for 10 years. His approach to PK modelling is robust and and insightful. His knowledge of PK modelling, formulations and biopharmaceutics means that he is uniquely placed to interpret PK profiles and predict how formulations are behaving. He has provided impactful advice over the years. He is always a pleasure to work with!"
Director, Clinical Pharmacology at ViiV Healthcare
"I've had the privilege of working with John on several antiviral drug projects over the past 10 years. John's unique skill set allows him to effectively integrate in vitro, preclinical and clinical pharmacology study data to understand drug absorption and enhance formulation development. John’s specific contributions have included deconvolution and PK analyses to describe and understand absorption differences between patients and healthy volunteers, as well as bioavailability differences between pediatric and adult subjects. His use of modeling and simulation to predict the performance of fixed dose combination formulations provided valuable input into the design of a clinical relative bio study."